VCM
GILD icon

Versant Capital Management’s Gilead Sciences GILD Stock Holding History

Versant Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$689K Sell
5,454
-459
-8% -$60.5K 0.06% 200
2026
Q1 		$824K Buy
5,913
+1,496
+34% +$209K 0.08% 148
2025
Q4 		$542K Buy
4,417
+182
+4% +$22.1K 0.07% 206
2025
Q3 		$470K Buy
4,235
+59
+1% +$6.71K 0.06% 221
2025
Q2 		$463K Buy
4,176
+1,304
+45% +$139K 0.07% 192
2025
Q1 		$322K Buy
2,872
+1,814
+171% +$187K 0.05% 268
2024
Q4 		$97.7K Buy
1,058
+361
+52% +$32.5K 0.02% 321
2024
Q3 		$58.4K Buy
697
+71
+11% +$5.42K 0.01% 395
2024
Q2 		$43K Sell
626
-171
-21% -$11.4K 0.01% 427
2024
Q1 		$58.4K Sell
797
-47
-6% -$3.61K 0.02% 259
2023
Q4 		$68.4K Sell
844
-209
-20% -$16.3K 0.02% 234
2023
Q3 		$78.9K Sell
1,053
-3,416
-76% -$263K 0.03% 206
2023
Q2 		$344K Sell
4,469
-10
-0.2% -$798 0.11% 86
2023
Q1 		$372K Buy
4,479
+238
+6% +$19.7K 0.12% 79
2022
Q4 		$364K Hold
4,241
– – 0.13% 74
2022
Q3 		$262K Hold
4,241
– – 0.1% 87
2022
Q2 		$262K Sell
4,241
-90
-2% -$5.57K 0.1% 93
2022
Q1 		$257K Buy
4,331
+111
+3% +$7.09K 0.08% 96
2021
Q4 		$306K Hold
4,220
– – 0.1% 86
2021
Q3 		$295K Buy
4,220
+18
+0.4% +$1.26K 0.1% 80
2021
Q2 		$289K Buy
4,202
+35
+0.8% +$2.34K 0.11% 79
2021
Q1 		$269K Buy
4,167
+50
+1% +$3.22K 0.1% 87
2020
Q4 		$239K Buy
4,117
+26
+0.6% +$1.57K 0.09% 86
2020
Q3 		$258K Sell
4,091
-35
-0.8% -$2.43K 0.12% 84
2020
Q2 		$317K Sell
4,126
-2,217
-35% -$170K 0.15% 69
2020
Q1 		$474K Buy
6,343
+5,565
+715% +$385K 0.25% 48
2019
Q4 		$50K Sell
778
-58
-7% -$3.78K 0.03% 213
2019
Q3 		$52K Sell
836
-4
-0.5% -$261 0.02% 210
2019
Q2 		$56K Sell
840
-264
-24% -$17.4K 0.03% 199
2019
Q1 		$71K Buy
1,104
+1
+0.1% +$66 0.03% 192
2018
Q4 		$68K Hold
1,103
– – 0.03% 182
2018
Q3 		$85K Sell
1,103
-14
-1% -$1.06K 0.03% 172
2018
Q2 		$79K Sell
1,117
-15
-1% -$1.06K 0.03% 185
2018
Q1 		$85K Sell
1,132
-14
-1% -$1.11K 0.04% 177
2017
Q4 		$82K Sell
1,146
-9
-0.8% -$683 0.03% 194
2017
Q3 		$93K Hold
1,155
– – 0.05% 146
2017
Q2 		$81K Buy
1,155
+53
+5% +$3.53K 0.04% 162
2017
Q1 		$74K Sell
1,102
-37
-3% -$2.6K 0.04% 179
2016
Q4 		$81K Buy
1,139
+58
+5% +$4.31K 0.05% 165
2016
Q3 		$85K Buy
1,081
+11
+1% +$894 0.05% 155
2016
Q2 		$89K Sell
1,070
-16
-1% -$1.42K 0.05% 140
2016
Q1 		$99K Sell
1,086
-36
-3% -$3.25K 0.06% 125
2015
Q4 		$113K Buy
+1,122
New +$117K 0.07% 115

Other funds holding GILD

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
CIM
Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return

Versant Capital Management's GILD Position: Q2 2026 in Review

Versant Capital Management reduced its Gilead Sciences (GILD) stake by 7.8% in Q2 2026, selling an estimated $60.5K and leaving 5,454 shares worth $689K. The position accounts for 0.06% of the portfolio, ranked #200.

Versant Capital Management first reported a position in GILD in Q4 2015 and has held it in 43 quarters since. The position peaked at $824K in Q1 2026. 610 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Versant Capital Management held 5,454 shares of Gilead Sciences worth $689K as of Q2 2026.
  • Versant Capital Management sold 459 Gilead Sciences shares in Q2 2026, an estimated $60.5K.
  • Gilead Sciences made up 0.06% of Versant Capital Management's portfolio in Q2 2026, its #200 holding.
  • Versant Capital Management first reported a position in Gilead Sciences in Q4 2015 and has held it in 43 quarters since.
  • Versant Capital Management's Gilead Sciences position peaked at $824K in Q1 2026.
  • 610 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.